Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 2/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746292 | 0.92 | GSK3B (0.34) | KITPTPN11GSK3BFYNNT5E | |
| SCHEMBL13745686 | 0.85 | KDR (0.35) | PTPN11GSK3B | |
| SCHEMBL13745903 | 0.82 | MAPK8 (0.37) | KITMAPK8MAPK9MAPK10GSK3B | |
| SCHEMBL13746324 | 0.81 | KDR (0.44) | KITPTPN11 | |
| SCHEMBL13609303 | 0.80 | ALDH1A1 (0.38) | MAPK8MAPK9MAPK10PTPN11GSK3B | |
| SCHEMBL13745855 | 0.80 | CAMKK2 (0.36) | FYN | |
| SCHEMBL13745732 | 0.80 | KDR (0.49) | PTPN11 | |
| SCHEMBL13745690 | 0.80 | GSK3B (0.34) | GSK3B | |
| SCHEMBL13609212 | 0.79 | AAK1 (0.38) | MAPK8MAPK9MAPK10GSK3BPDGFRB | |
| SCHEMBL13745703 | 0.79 | KDR (0.38) | PTPN11GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KIT 3148/4885MAPK8 50/4885MAPK9 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.